Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia

NCT03904251 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT03904251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03904251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
July 18, 2019
Completion date
October 25, 2023
Enrollment
13 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia